Cancer Biomarkers and Their Role in Personalized Medicine: Advances, Applications, Challenges and Future Prospects

Abstract

Cancer biomarkers have become central to the development of personalized medicine by enabling clinicians and researchers to characterize tumors according to their molecular, cellular, genetic, and physiological properties. Cancer is a highly heterogeneous disease in which tumors arising from the same anatomical site can possess substantially different biological characteristics and responses to therapy. Consequently, conventional treatment strategies based primarily on tumor location, histological classification, and stage may not adequately capture individual patient differences. Biomarkers provide measurable indicators that can assist in cancer detection, diagnosis, prognosis, treatment selection, monitoring, and prediction of therapeutic response. Advances in genomics, proteomics, transcriptomics, epigenomics, liquid biopsy, next-generation sequencing, artificial intelligence, and molecular imaging have significantly expanded the range and utility of cancer biomarkers. Genetic alterations such as EGFR mutations, ALK rearrangements, BRAF mutations, KRAS alterations, HER2 amplification, BRCA1/2 abnormalities, and microsatellite instability have demonstrated the clinical value of biomarker-guided treatment. Immune biomarkers, including PD-L1 expression, tumor mutational burden, and mismatch-repair deficiency, have also influenced immunotherapy selection. Liquid biopsy and circulating tumor DNA provide opportunities for minimally invasive, longitudinal monitoring of tumor evolution and treatment resistance. Despite these advances, substantial challenges remain, including tumor heterogeneity, biomarker instability, false-positive and false-negative results, limited clinical validation, variant interpretation, high testing costs, and unequal access to advanced molecular diagnostics. The future of cancer biomarker research is expected to move toward integrated multi-omics profiling, spatial biomarkers, artificial intelligence, real-time molecular monitoring, and composite biomarker models. This paper examines the scientific foundations, classifications, clinical applications, technological advances, limitations, ethical considerations, and future prospects of cancer biomarkers in personalized medicine.